Revefenacin (Theravance Biopharma/Mylan) is a long-acting muscarinic antagonist (LAMA) that will join a very crowded COPD market. The drug will be in direct competition with the gold-standard therapy Spiriva (tiotropium; Boehringer Ingelheim), as well as a host of other LAMA therapies that are available for the treatment of COPD. Revefenacin’s positive clinical trial data may help its uptake, but its late entry to the COPD market and its formulation as a nebulized therapy will significantly limit its potential.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726